FDA Halts Use of Some COVID Monoclonal Antibodies Due to Omicron
Bamlanivimab/etesevimab and casirivimab/imdevimab are highly unlikely to be active against the Omicron variant, which now makes up virtually all cases of COVID-19 in the United States, the FDA says.
United States Geralde Harmon Patrizia Cavazzoni Eli Lilly Sotrovimab Glaxosmithkline Vir National Institutes Of Health
Source: medscape.com